Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Factor VIII; von Willebrand factor
Octapharma Ltd
B02BD06
Factor VIII; von Willebrand factor
500unit ; 500unit
Powder and solvent for solution for infusion
Intravenous
No Controlled Drug Status
Never Valid To Prescribe As A VMP
BNF: ; GTIN: 5060237670334
PACKAGE LEAFLET: INFORMATION FOR THE USER WILATE 500, 500 IU VWF/500 IU FVIII, powder and solvent for solution for injection WILATE 1000, 1000 IU VWF/1000 IU FVIII , powder and solvent for solution for injection Human von Willebrand factor/human coagulation factor VIII READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Please keep this leaflet. You may need to read it again. • If you have further questions, ask your doctor or your pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Wilate is and what it is used for 2. What you need to know before you use Wilate 3. How to use Wilate 4. Possible side effects 5. How to store Wilate 6. Contents of the pack and other information 1. WHAT WILATE IS AND WHAT IT IS USED FOR Wilate belongs to the pharmacotherapeutic group of medicines called clotting factors and contains human von Willebrand factor (VWF) and human blood coagulation factor VIII (FVIII). Together these two proteins are involved in blood clotting. Von Willebrand disease Wilate is used to treat and prevent bleeding in patients with von Willebrand disease (VWD), which in fact is a family of related diseases. VWD is a disturbance of blood coagulation where bleeding can go on for longer than expected. This is either due to a lack of VWF in the blood or due to VWF that does not work the way it should. Haemophilia A Wilate is used to treat and prevent bleeding in patients with haemophilia A. This is a condition in which bleeding can go on for longer than expected. It is due to an inborn lack of FVIII in the blood. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE WILATE DO NOT USE WILATE • if you are allergic (hypersensitive) to human von Willebrand facto Read the complete document
OBJECT 1 WILATE Summary of Product Characteristics Updated 15-Dec-2014 | Octapharma Limited 1. Name of the medicinal product Wilate 500, 500 IU VWF/500 IUFVIII, powder and solvent for solution for injection Wilate 1000, 1000 IU VWF/1000 IUFVIII, powder and solvent for solution for injection 2. Qualitative and quantitative composition Wilate, produced from the plasma of human donors, is presented as a powder and solvent for solution for injection containing nominally 500 IU/1000 IU human von Willebrand factor (VWF) and human coagulation factor VIII (FVIII) per vial. The product contains approximately 100 IU/ml human von Willebrand factor when reconstituted with 5 ml/10 ml Water for Injections with 0.1 % Polysorbat 80. The specific activity of Wilate is ≥ 67 IU VWF:RCo/mg protein. The VWF potency (IU) is measured according to ristocetin cofactor activity (VWF:RCo) compared to the International Standard for von Willebrand Factor Concentrate (WHO). The product contains approximately 100 IU/ml human coagulation factor VIII when reconstituted with 5 ml/10 ml Water for Injections with 0.1% Polysorbate 80. The FVIII potency (IU) is determined using the European Pharmacopoeia chromogenic assay. The specific activity of Wilate is ≥ 67 IU FVIII:C/mg protein. For the full list of excipients, see section 6.1. 3. Pharmaceutical form Powder and solvent for solution for injection. Freeze-dried powder: white or pale yellow powder or crumbly solid. 4. Clinical particulars 4.1 Therapeutic indications Von Willebrand disease (VWD) Prevention and treatment of haemorrhage or surgical bleeding in von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or contra-indicated. Haemophilia A Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital FVIII deficiency). 4.2 Posology and method of administration Treatment should be under the supervision of a physician experienced in the treatment of coagulation disorders. The product is of single use and the full content of the vial should Read the complete document